Research programme: oral cancer vaccines - UbiVac/Janssen Biotech

Drug Profile

Research programme: oral cancer vaccines - UbiVac/Janssen Biotech

Alternative Names: Oral cancer vaccine - UbiVac/Janssen Biotech

Latest Information Update: 20 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UbiVac
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Head and neck cancer

Most Recent Events

  • 29 Sep 2015 UbiVac and Janssen Biotech collaborate to develop a vaccine for oral cancer in USA
  • 29 Sep 2015 Preclinical trials in Head and neck cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top